PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18250276-0 2008 Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio". Losartan 72-80 renin Homo sapiens 152-157 18475165-8 2008 Plasma renin activity was positively correlated with blood pressure responses to losartan (P values 0.001-0.005) and bisoprolol (P values 0.03-0.17), and negatively with blood pressure responses to hydrochlorothiazide (P values 0.01-0.07). Losartan 81-89 renin Homo sapiens 7-12 18250276-0 2008 Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio". Losartan 72-80 renin Homo sapiens 196-201 17524880-0 2007 Renin-angiotensin system polymorphisms and hemoglobin level in renal allografts: a comparative study between losartan and enalapril. Losartan 109-117 renin Homo sapiens 0-5 17703637-2 2007 The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT1) receptor with losartan. Losartan 162-170 renin Homo sapiens 4-9 17222813-0 2007 Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Losartan 14-22 renin Homo sapiens 85-90 15743363-2 2005 We evaluated the relationship between genetic polymorphisms of the renin-angiotensin system (A1166C angiotensin II type 1 receptor (AT1R), angiotensinogen T174M and M235T, and angiotensin-converting enzyme I/D) and the effects of losartan on portal and systemic hemodynamic in patients with cirrhosis and portal hypertension. Losartan 230-238 renin Homo sapiens 67-72 16685219-5 2006 RESULTS: Extracellular renin (128 pmol Ang I/ml per min) plus angiotensinogen (110 pmol angiotensin I generated by renin to exhaustion) incremented the peak ICa density significantly, an effect suppressed by enalapril maleate (10 mol/l) or by losartan (10 mol/l) added to the bath, indicating that the effect of renin plus angiotensinogen was related to the formation of angiotensin I and its conversion to angiotensin II at the surface cell membrane. Losartan 243-251 renin Homo sapiens 23-28 16685219-6 2006 Renin internalization seems to increment the ICa because intracellular dialysis of renin (128 pmol Ang I/ml per min) plus angiotensinogen (110 pmol angiotensin I generated by renin to exhaustion) also increased the peak ICa density significantly, an effect suppressed by intracellular losartan (10 mol/l) but not by extracellular losartan (10 mol/l). Losartan 285-293 renin Homo sapiens 0-5 16685219-6 2006 Renin internalization seems to increment the ICa because intracellular dialysis of renin (128 pmol Ang I/ml per min) plus angiotensinogen (110 pmol angiotensin I generated by renin to exhaustion) also increased the peak ICa density significantly, an effect suppressed by intracellular losartan (10 mol/l) but not by extracellular losartan (10 mol/l). Losartan 330-338 renin Homo sapiens 0-5 16169319-7 2005 Eplerenone consistently reduced blood pressure regardless of baseline active plasma renin levels whereas losartan reduced blood pressure more effectively in patients with higher baseline active renin levels. Losartan 105-113 renin Homo sapiens 194-199 14638911-5 2003 When similar experiments were performed with the addition of either captopril or losartan, there was a significant increase in the renin gene expression by HMC, whereas the synthesis of TGF-beta was markedly reduced. Losartan 81-89 renin Homo sapiens 131-136 15218473-2 2004 Inhibitors of the renin-angiotensin system, such as losartan, have potential to prevent recurrent stenosis; however, to date, efficacy has not been demonstrated in either animal models or human beings. Losartan 52-60 renin Homo sapiens 18-23 12073593-0 2002 [Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients]. Losartan 24-32 renin Homo sapiens 84-89 12233220-4 2002 Interestingly enough, three clinical trials recently reported concordant results showing that the inhibition of the renin-angiotensin system significantly reduces the risk of developing type 2 diabetes in patients at high risk of vascular complications, essentially with hypertension: the CAPPP trial with captopril (-14%, p = 0.39), the HOPE study with ramipril (-34%, p < 0.001) and the LIFE study with losartan (-25%, p < 0.001). Losartan 408-416 renin Homo sapiens 116-121 12543883-11 2003 Plasma renin was significantly increased from baseline after initiation of losartan treatment and stabilized after 7 days (P<0.01). Losartan 75-83 renin Homo sapiens 7-12 12563562-4 2002 It is likely that drugs blocking the renin-angiotensin-aldosterone system cause greater regression of LVH than other agents and this is probably the mechanism that explains the superiority of losartan over atenolol in the LIFE study. Losartan 192-200 renin Homo sapiens 37-42 11791032-12 2002 In contrast, the combination therapy with losartan and quinapril, which results in a higher degree of inhibition of the renin-angiotensin system, could suppress the cardiac sympathetic activity effectively. Losartan 42-50 renin Homo sapiens 120-125 11971755-2 2002 With perfusion, plasma renin activity (PRA) increased markedly from 3 +/- 1 to 90 +/- 17 ng Ang I/ml/h (control), and from 4 +/- 1 to 70 +/- 8 ng Ang I/ml/h (Losartan), plasma Ang II increased from 86 +/- 63 to 482 +/- 111 pg/ml (control), and from 73 +/- 42 to 410 +/- 91 pg/ml (Losartan). Losartan 158-166 renin Homo sapiens 23-28 11971755-2 2002 With perfusion, plasma renin activity (PRA) increased markedly from 3 +/- 1 to 90 +/- 17 ng Ang I/ml/h (control), and from 4 +/- 1 to 70 +/- 8 ng Ang I/ml/h (Losartan), plasma Ang II increased from 86 +/- 63 to 482 +/- 111 pg/ml (control), and from 73 +/- 42 to 410 +/- 91 pg/ml (Losartan). Losartan 280-288 renin Homo sapiens 23-28 11523316-1 2001 The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism. Losartan 81-89 renin Homo sapiens 213-218 11509454-8 2001 Intracerebroventricular (ICV) injection of human REN (hREN) in conscious unrestrained mice elicited a pressor response, which was abolished by ICV preinjection of losartan. Losartan 163-171 renin Homo sapiens 49-52 11509454-8 2001 Intracerebroventricular (ICV) injection of human REN (hREN) in conscious unrestrained mice elicited a pressor response, which was abolished by ICV preinjection of losartan. Losartan 163-171 renin Homo sapiens 54-58 11479463-8 2001 RESULTS: Treatment with losartan decreased systolic blood pressure (141 +/- 3 vs 135 +/- 4 mm Hg, P =.04) and increased plasma renin activity (1.2 +/- 0.4 vs 2.7 +/- 0.5 ng/mL/h, P =.001). Losartan 24-32 renin Homo sapiens 127-132 11130773-7 2000 Pretreatment with losartan had little effect on baseline MAP, but increased plasma renin activity, and virtually eliminated the pressor response to Ang II infusion. Losartan 18-26 renin Homo sapiens 83-88 10862636-9 2000 Under losartan and enalapril, filtration fraction fell (P=0.02), plasma renin activity increased (P<0.05) and urinary aldosterone concentration decreased (P=0.02). Losartan 6-14 renin Homo sapiens 72-77 10410812-3 1999 For this reason, the authors undertook two studies in a model of mild salt depletion of a normotensive subject, which showed additive effects on the lowering of the blood pressure and renin secretion during combined administration of captopril and losartan, then enalapril and losartan. Losartan 248-256 renin Homo sapiens 184-189 10821336-5 2000 Plasma renin activity (PRA) was significantly stimulated during diuretic treatment (1.35 +/- 0.21 v 0.34 +/- 0.06 ng mL(-1) x h(-1) [P < .001]) and further increased after losartan (6.39 +/- 1.16 ng mL(-1) x h(-1) [P < .001]). Losartan 175-183 renin Homo sapiens 7-12 28425793-6 2000 The large interindividual variability of EXP-3174 levels in subjects who received losartan revealed a significant correlation between active renin and peak drug levels ( r = 0.77, n = 16, p < 0.01). Losartan 82-90 renin Homo sapiens 141-146 10576791-0 1999 Blood pressure and renin angiotensin system responses to initiation of treatment with captopril or losartan in heart failure. Losartan 99-107 renin Homo sapiens 19-24 10885588-8 2000 Losartan administration was accompanied by a decline in plasma aldosterone level as well as by an increase in plasma renin activity. Losartan 0-8 renin Homo sapiens 117-122 10608722-7 1999 The rise of plasma renin activity with losartan (221 +/- 26% at the 3,000 ml stage) was significantly greater than that without losartan (144 +/- 2.4%). Losartan 39-47 renin Homo sapiens 19-24 10483973-6 1999 RESULTS: Losartan, EXP3174 and captopril elevated plasma renin activities and comparably and significantly reduced mean arterial pressure. Losartan 9-17 renin Homo sapiens 57-62 10424062-2 1999 Apart from optimum hypotensive effect and modulating influence on morphofunctional parameters of the heart losartan was found to be endowed with a broad spectrum of neurohumoral effects (reduction in the ejection of catecholamines, natriuretic hormone, stabilization of indices for the renin-angiotensin system etc.). Losartan 107-115 renin Homo sapiens 286-291 10404959-4 1999 RESULTS: The area under the curve (0-24 h) for plasma active renin did not differ significantly between 8 mg candesartan cilexetil and 50 mg losartan, but was significantly higher for 16 than for 8 mg candesartan cilexetil or for 50 mg losartan. Losartan 141-149 renin Homo sapiens 61-66 10404959-4 1999 RESULTS: The area under the curve (0-24 h) for plasma active renin did not differ significantly between 8 mg candesartan cilexetil and 50 mg losartan, but was significantly higher for 16 than for 8 mg candesartan cilexetil or for 50 mg losartan. Losartan 236-244 renin Homo sapiens 61-66 10404959-7 1999 The area under the curve (0-24 h) for plasma active renin was significantly correlated to that for plasma levels of the active metabolite of losartan, EXP 3174 (r = 0.65, n = 16, P< 0.01). Losartan 141-149 renin Homo sapiens 52-57 9853270-8 1998 However, when Y-1 reporter cells were transfected with human angiotensin II receptor type 1 (AT1) cDNA, hREN promoter activity was dose-dependently down-regulated by Ang II, which was blockable by losartan, an AT1-selective antagonist. Losartan 197-205 renin Homo sapiens 104-108 10073846-4 1999 Selective, angiotensin type 1 receptor antagonism with losartan, which inhibits the effects of angiotensin II regardless of its source at the receptor level, may provide more complete blockade of the renin-angiotensin system. Losartan 55-63 renin Homo sapiens 200-205 9247766-5 1997 The combination of captopril 50 mg and losartan 50 mg had additive effects on blood pressure fall and renin release in sodium-depleted normotensive subjects. Losartan 39-47 renin Homo sapiens 102-107 9604859-3 1998 Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Losartan 0-8 renin Homo sapiens 53-58 9247766-6 1997 When compared to enalapril 10 mg and the doubling of its dose, the combination of losartan 50 mg and enalapril 10 mg significantly increased both the area under the time curve of mean blood pressure fall and plasma active renin levels. Losartan 82-90 renin Homo sapiens 222-227 8913546-11 1996 Among blacks, the mean response of losartan was lower, which is not surprising given the lesser activation of the renin-angiotensin system in this population. Losartan 35-43 renin Homo sapiens 114-119 9040450-0 1997 Additive effects of losartan and enalapril on blood pressure and plasma active renin. Losartan 20-28 renin Homo sapiens 79-84 9040450-1 1997 The combination of single oral doses of an angiotensin I-converting enzyme inhibitor (captopril) and a type 1 angiotensin II receptor antagonist (losartan) has additive effects on blood pressure fall and renin release in sodium-depleted normotensive subjects. Losartan 146-154 renin Homo sapiens 204-209 9040450-6 1997 The losartan-enalapril combination is more effective in decreasing blood pressure and increasing plasma active renin than doubling of the enalapril dose. Losartan 4-12 renin Homo sapiens 111-116 8549037-7 1996 Both losartan and enalapril increased plasma renin concentration compared with placebo. Losartan 5-13 renin Homo sapiens 45-50 8998251-8 1995 We conclude that 1) losartan decreases blood pressure in women with essential hypertension and low plasma renin activity; 2) the antihypertensive effect is not associated with sustained changes in renal or extrarenal PG production; and 3) losartan reduces plasma aldosterone and serum uric acid concentrations in patients with essential hypertension. Losartan 20-28 renin Homo sapiens 106-111 8751032-4 1995 The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively). Losartan 48-56 renin Homo sapiens 23-28 8554732-0 1995 Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Losartan 28-36 renin Homo sapiens 68-73 8554732-0 1995 Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Losartan 28-36 renin Homo sapiens 85-90 8554732-4 1995 We studied the effect of acute and chronic (42 days) stimulation of the renin angiotensin system with the AT1 selective angiotensin II receptor antagonist losartan on plasma active renin, active renin glycoforms separated by isoelectric focusing, and inactive renin in 11 essential hypertensive patients. Losartan 155-163 renin Homo sapiens 181-186 8554732-4 1995 We studied the effect of acute and chronic (42 days) stimulation of the renin angiotensin system with the AT1 selective angiotensin II receptor antagonist losartan on plasma active renin, active renin glycoforms separated by isoelectric focusing, and inactive renin in 11 essential hypertensive patients. Losartan 155-163 renin Homo sapiens 181-186 8554732-4 1995 We studied the effect of acute and chronic (42 days) stimulation of the renin angiotensin system with the AT1 selective angiotensin II receptor antagonist losartan on plasma active renin, active renin glycoforms separated by isoelectric focusing, and inactive renin in 11 essential hypertensive patients. Losartan 155-163 renin Homo sapiens 181-186 8554732-5 1995 A single 50 mg dose of losartan significantly increased plasma active renin concentration (ARC) from a pretreatment baseline of 3.2 +/- 1.1 to 7.2 +/- 2.3 ng AI/mL/h, 4 h postdose. Losartan 23-31 renin Homo sapiens 70-75 8554732-8 1995 Plasma ARC also increased significantly from 7.8 +/- 3.1 to 14.9 +/- 6.0 ng AI/mL/h acutely after the losartan dose on day 42 primarily due to increased plasma concentrations of less negatively charged active renin forms. Losartan 102-110 renin Homo sapiens 209-214 8554732-11 1995 Chronic stimulation of renal renin secretion with losartan increased plasma concentrations of both active and inactive renin, but did not alter the proportions of active renin forms. Losartan 50-58 renin Homo sapiens 29-34 7596116-1 1995 We examined the haemodynamic and renal response to oral losartan potassium (100 mg) during activation of the renin system in humans. Losartan 56-74 renin Homo sapiens 109-114 7843751-0 1995 Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Losartan 23-31 renin Homo sapiens 89-94 7843751-6 1995 Four hours after dosing, compared with the run-in day, 100 mg losartan increased plasma renin activity 1.7-fold and Ang II 2.5-fold, whereas enalapril increased plasma renin activity 2.8-fold and decreased Ang II 77%. Losartan 62-70 renin Homo sapiens 88-93 7843751-10 1995 After the last dose of losartan, plasma renin activity and Ang II changes were similar to placebo changes by 36 hours. Losartan 23-31 renin Homo sapiens 40-45 8554732-11 1995 Chronic stimulation of renal renin secretion with losartan increased plasma concentrations of both active and inactive renin, but did not alter the proportions of active renin forms. Losartan 50-58 renin Homo sapiens 119-124 8554732-11 1995 Chronic stimulation of renal renin secretion with losartan increased plasma concentrations of both active and inactive renin, but did not alter the proportions of active renin forms. Losartan 50-58 renin Homo sapiens 119-124 8554732-13 1995 Chronic stimulation of renal renin secretion with losartan presumably increased renin gene expression and resulted in increased constitutive secretion of inactive renin, increased constitutive secretion of negatively charged active renin forms, and increased renal storage of less negatively charged renin forms that were then available for acute regulated release. Losartan 50-58 renin Homo sapiens 29-34 8554732-13 1995 Chronic stimulation of renal renin secretion with losartan presumably increased renin gene expression and resulted in increased constitutive secretion of inactive renin, increased constitutive secretion of negatively charged active renin forms, and increased renal storage of less negatively charged renin forms that were then available for acute regulated release. Losartan 50-58 renin Homo sapiens 80-85 8554732-13 1995 Chronic stimulation of renal renin secretion with losartan presumably increased renin gene expression and resulted in increased constitutive secretion of inactive renin, increased constitutive secretion of negatively charged active renin forms, and increased renal storage of less negatively charged renin forms that were then available for acute regulated release. Losartan 50-58 renin Homo sapiens 80-85 8554732-13 1995 Chronic stimulation of renal renin secretion with losartan presumably increased renin gene expression and resulted in increased constitutive secretion of inactive renin, increased constitutive secretion of negatively charged active renin forms, and increased renal storage of less negatively charged renin forms that were then available for acute regulated release. Losartan 50-58 renin Homo sapiens 80-85 8554732-13 1995 Chronic stimulation of renal renin secretion with losartan presumably increased renin gene expression and resulted in increased constitutive secretion of inactive renin, increased constitutive secretion of negatively charged active renin forms, and increased renal storage of less negatively charged renin forms that were then available for acute regulated release. Losartan 50-58 renin Homo sapiens 80-85 7641363-10 1995 After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05). Losartan 15-23 renin Homo sapiens 83-88 7641363-10 1995 After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05). Losartan 177-185 renin Homo sapiens 83-88 18800452-3 1995 DOSE-FINDING: Over the last few years, studies in normotensive subjects have demonstrated that the minimal dose of losartan that produces maximal efficacy is 40-80 mg. Losartan has a long duration of action and its ability to produce a sustained blockade of the renin-angiotensin system is due almost exclusively to the active metabolite E3174. Losartan 115-123 renin Homo sapiens 262-267 18800452-3 1995 DOSE-FINDING: Over the last few years, studies in normotensive subjects have demonstrated that the minimal dose of losartan that produces maximal efficacy is 40-80 mg. Losartan has a long duration of action and its ability to produce a sustained blockade of the renin-angiotensin system is due almost exclusively to the active metabolite E3174. Losartan 168-176 renin Homo sapiens 262-267 18800452-4 1995 HORMONAL EFFECTS: Angiotensin II receptor blockade with losartan induces an expected increase in plasma renin activity and plasma angiotensin II levels. Losartan 56-64 renin Homo sapiens 104-109 7595905-0 1995 Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. Losartan 11-19 renin Homo sapiens 27-32 7685442-1 1993 In a dose-ranging study, the angiotensin type I receptor antagonist losartan (DuP753/MK954) was administered orally to normal volunteers in whom the renin-angiotensin system (RAS) had been activated by a low sodium diet (40 mmol) and frusemide (40 mg twice daily) for 3 days before study. Losartan 68-76 renin Homo sapiens 149-154 7634303-7 1994 Virtually all of the known actions of Ang II, e.g. those defined by Ang II itself, saralasin, ACE or renin-inhibitors are blocked by losartan, emphasizing the major role of this distinct Ang II receptor subtype in mediating the responses of Ang II. Losartan 133-141 renin Homo sapiens 101-106 7685442-10 1993 Our results indicate a BP and plasma renin dose-response relation for the orally active angiotensin II (AII) receptor blocker losartan in normotensive subjects with an activated RAS. Losartan 126-134 renin Homo sapiens 37-42 8315513-5 1993 ACTION OF LOSARTAN: Losartan selectively inhibits all Ang II responses that have been studied and lowers blood pressure in several animal models of renin-dependent hypertension. Losartan 10-18 renin Homo sapiens 148-153 8315513-6 1993 In animals, the antihypertensive efficacy of losartan is similar to that of angiotensin converting enzyme (ACE) inhibitors but, unlike ACE inhibitors, losartan is a more selective inhibitor of the renin-angiotensin system since it does not affect the metabolism of kinins. Losartan 151-159 renin Homo sapiens 197-202 8315513-5 1993 ACTION OF LOSARTAN: Losartan selectively inhibits all Ang II responses that have been studied and lowers blood pressure in several animal models of renin-dependent hypertension. Losartan 20-28 renin Homo sapiens 148-153 8451266-1 1993 The AT-1 receptor antagonist, losartan potassium, produced a large rise in plasma renin activity (PRA) after peripheral, but not intracerebroventricular (ICV), administration. Losartan 30-48 renin Homo sapiens 82-87 8451266-2 1993 Peripheral, but not ICV administration of losartan also augmented the release of renin induced by peripheral administration of the beta-adrenergic agonist, isoproterenol. Losartan 42-50 renin Homo sapiens 81-86 29727629-0 2018 Losartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. Losartan 0-8 renin Homo sapiens 63-68 1636762-3 1992 Losartan induced a significant rise in plasma renin activity (PRA) and plasma angiotensin II levels (P less than 0.01 and P less than 0.001, respectively), in association with a fall in the plasma aldosterone-to-PRA ratio (P less than 0.001) and plasma atrial natriuretic peptide (P less than 0.05). Losartan 0-8 renin Homo sapiens 46-51 1291647-5 1992 The recent development of specific and highly potent Ang II type 1 subtype receptor antagonists such as losartan (DuP753, MK954) have provided a new opportunity to inhibit the renin-angiotensin system, and this is currently being explored in hypertensive patients. Losartan 104-112 renin Homo sapiens 176-181 2013151-14 1991 Similar to angiotensin converting enzyme and renin inhibitors, DuP 753 induced a dose-dependent increase in plasma renin that was more pronounced on the eighth than on the first day of drug administration. Losartan 63-70 renin Homo sapiens 115-120 27548072-10 2016 Losartan significantly increased renin levels and reduced aldosterone levels in the group without OSA. Losartan 0-8 renin Homo sapiens 33-38 28577742-3 2017 Fixed doses of an angiotensin-converting enzyme inhibitor or renin inhibitor added-on losartan failed to exert any additional renoprotective effect as compared with losartan monotherapy in patients with type 2 diabetes and overt nephropathy. Losartan 86-94 renin Homo sapiens 61-66 25655494-4 2015 RESULTS: ACEi and losartan-stimulated fibroblasts showed an increase in the expression of TGF-beta1, Collagen-Ialpha1 (Col-Ialpha1), and renin (except losartan) vs PolR2A (p < 0.05), and upregulation of TGF-beta1 protein (p < 0.01), except with aliskiren. Losartan 18-26 renin Homo sapiens 137-142 21331055-4 2011 RESULTS: At rest, losartan doubled plasma renin (P = 0.01) and ANG II (P = 0.03) concentrations, and lowered BP (P < 0.01) yet had no effect on MSNA burst frequency or incidence. Losartan 18-26 renin Homo sapiens 42-47 21326341-9 2011 Therefore, celecoxib could be used in renin-dependent hypertensive patients who receive losartan, without fear of a rise in their blood pressure. Losartan 88-96 renin Homo sapiens 38-43